• Transactions of the Korean Society of Mechanical Engineers B
• /
• v.36 no.6
• /
• pp.601-607
• /
• 2012

In this study, we performed computational fluid dynamic simulations to explore how the detailed design of drug-eluting stents affects both the flow field in the vicinity of the stent as well as the concentration of the eluted drug at the endothelial cell surface. Simulations were performed on three idealized stent geometries we developed and on geometries approximating three commercial stents,: Medtronic's Aurora stent, Cordis's BX Velocity stent, and Boston Scientific's Wallstent. An important contribution of the present study is the introduction of the stent effectiveness index (EI), which provides a quantitative assessment of stent performance and an objective basis for comparing the performance of different stents. Among the three commercial stents studied, our simulations have revealed that the BX Velocity stent is associated with the lowest in-stent EI values for the range of flow Reynolds numbers studied ($200{\leq}Re{\leq}800$). In addition to commercial stent designs, we investigated the EI in three idealized stents and determined that a spiral stent provides excellent performance (low EI) under all flow conditions investigated.

• KSBB Journal
• /
• v.18 no.2
• /
• pp.107-110
• /
• 2003

Biodegradable polymers, poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate) (PHB), and medium chain length polyhydroxyalkanoates (MCL-PHA) containing rose bengal (model drug) were coated onto the surface of stainless steel (stent materials) and their in vitro release characteristics were investigated. Drug release increased with; decreasing PLGA concentration, increasing rose bengal concentration, and Increasing dip-coating duration. The order of drug release from the polymer coating was: PHB > PLGA > MCL-PHA. These results suggest that drug release can be controlled by: changing the concentration and type of polymer, the drug concentration, and the dip-coating duration.

• Polymer(Korea)
• /
• v.35 no.5
• /
• pp.483-487
• /
• 2011

For the preparation of effective non-vascular drug eluting stent (DES), pullulan acetate (PA) was investigated as a coating material for polytetrafluorethylene (PTFE)-covered stent. PA was coated on PTFE-covered stent (PTFE-stent) by dip coating technique, and then its surface morphology, drug release behavior and cellular toxicity were tested. Field emission-scanning electron microscopy (FE-SEM) result indicated that its surface was smoother after PA coating without any cracking. The sustained release behavior of paclitaxel from PA-coated PTFE membrane was observed for 80 days. Also, the biological stability of paclitaxel in the membrane was confirmed by annexin V binding assays. Furthermore, the antitumor activity was demonstrated by an in vivo test against CT-26 murine colorectal tumors. From the results, we concluded that PA was expected as a useful coating material to design an effective non-vascular DES.

• Polymer(Korea)
• /
• v.38 no.1
• /
• pp.93-97
• /
• 2014

Biodegradable drug-eluting stent has dual functions of supporting the lumen and treating internal tumor preventing the restenosis by releasing drug. In this study, the polycaprolactone (PCL) based three dimensional (3D) mesh loaded with paclitaxel (PTX) was presented by rapid prototyping (RP) technique of solid freeform fabrication (SFF) for biodegradable drug-eluting stent application. PCL has many advantageous properties such as good biocompatibility, good mechanical properties, and good drug permeability. PTX is widely used in the cancer treatment by inhibiting tumor cell proliferation. Analytical methods of HPLC and NMR were used for simultaneous quantification of PTX. Scanning electron microscopy (SEM) was performed to observe the architecture and morphologies of 3D mesh. The cytotoxicity assay results indicated released PTX's biological activity. This study provided that PCL based 3D mesh loaded with PTX by RP technique has great potential for biodegradable drug-eluting stent application.

• Transactions of the Korean Society of Mechanical Engineers B
• /
• v.35 no.10
• /
• pp.1053-1060
• /
• 2011

This study is performed to determine the drug concentration profiles of drug-eluting stents (DES) for an ideal circular ring stent and intertwined stent models for various Reynolds numbers (Re = 200, 400, and 800). The Navier.Stokes equations coupled with the advection-diffusion equation are solved numerically in order to determine how the flow patterns and drug deposition are affected in the in-stent and post-stent regions where flow separation and recirculation occur. The presence of DES within the arterial segment affects the local drug distribution in the flow field. As a result, the drug concentration for the intertwined stent is higher over the in-stent region in comparison with the ideal stents. For a given stent geometry, the local drug concentration in the in-stent region decreases with Reynolds number, while for a given Reynolds number, the local drug concentration is relatively insensitive to the stent geometry. The results show that drug concentration along the arterial wall is significantly higher within the in-stent and post-stent regions for the intertwined stent geometry than for the ideal stent geometries.

• Polymer(Korea)
• /
• v.34 no.2
• /
• pp.178-183
• /
• 2010

Medical metal stents inserted to patients with a cardiovascular disease associated with coronary artery system have relatively increased the survival rate. The development of new stents is, however, urgently required due to restenosis and late thrombosis generated in metal stents. To solve these problems, the biodegradable polymers such as poly(lactide-co-glycolide) (PLGA), poly(L-lactide)(PLLA), and poly ($\varepsilon$-caprolactone)(PCL) were mixed with alpha lipoic acid (ALA), which is well known to inhibit the proliferation of neointimal hyperplasia. Subsequently, the ALA-loaded polymers were coated on stainless steel by electrospray. The drug-eluting behaviors from the coated polymers were investigated according to kinds and concentrations of polymers, spray rates, and kinds of solvents. The drug-eluting rate from PCL with the lowest glass transition temperature was the fastest among three polymers and followed by PLGA and PLLA. The surface roughness increased as the spray rate was increased and also the drug-eluting rate was affected by kinds of solvents with different boiling point. It is expected that drug-eluting stent (DES) coated with ALA-loaded polymers can be applied practically for clinical applications by controlling the behavior of drug release.

• Polymer(Korea)
• /
• v.34 no.2
• /
• pp.172-177
• /
• 2010

Although many researchers have studied the efficacy of paclitaxel (PTX) on many cells during the last two decades, little work has been reported on the importance of release kinetics inhibiting cell proliferation. The aim of this study is to examine the release behavior of the PTX on various biodegradable polymers such as poly(lactic-co-glycolic acid)(PLGA), poly-L-lactide (PLLA), and polycaprolactone (PCL) for drug-eluting stents (DES). The PTX from the fabricated films was released for 8 weeks and the degree of degradation of the films was observed by FE-SEM. Although the degradation time of PCL was the slowest, the PTX release rate was the fastest among them and followed by PLGA and PLLA with the equivalent PTX concentration. It suggests that hydrophobic drug such as PTX from polymer with low $T_g$ like PCL could be moved easily and released rapidly in body temperature.

• Polymer(Korea)
• /
• v.36 no.2
• /
• pp.163-168
• /
• 2012

Recently, along with technology development of endoscopic equipment, the stent technology has been developed for the convenience of operation, shortening of recovery times, and reduction of patient's pain. In this study, paclitaxel-eluting metal stents for treatment of biliary benign stenosis were developed through an electrospray-coating method. Polyether-based polyurethane (PELLETHANE 2363-80AE$^{(R)}$)) and paclitaxel were coated onto the surface of a metallic stent and Pluronic F127 was used as an additive. As a result, physicochemical characterization of paclitaxel via SEM, FTIR, contact angle and XRD techniques revealed the information of solid state of paclitaxel-loaded PU film. The in vitro release profile showed a slower release rate with a higher content of paclitaxel.

• The Journal of the Korea Contents Association
• /
• v.13 no.12
• /
• pp.880-892
• /
• 2013

Stent thrombosis after successful drug-eluting stent(DES) implantation has been reported in around 1% of patients in clinical trials. However, the increased risk of ST associated with DES remains a matter of concern. From 1 June 2003 to 30 June 2013, we investigated clinical characteristics, in-hospital outcomes in 10,273 patients who underwent percutaneous coronary intervention in the Heart Center of CNUH. Overall incidence of ST was 1.30% (134 patients). The incidence of ST according to the stent generations and the timing of ST (n=total, early vs. late vs. very late) were 0.79% (n=81, 26 vs. 12 vs. 43) in first-generation, 0.38% (n=39, 21 vs. 9 vs. 9) in second-generation and 0.14% (n=14, 8 vs 3 vs. 3) in third-generation, (p=0.70). The mortality from ST was significantly higher in early ST group compared to the late and very late ST groups (18.2% vs. 8.3% vs. 3.6%, p=0.042). Overall incidence of ST after DES implantation was 1.30% (134 patients). The in-hospital mortality was significantly higher in early ST group compared to the late and very late ST groups.

• Journal of radiological science and technology
• /
• v.37 no.2
• /
• pp.109-116
• /
• 2014

Many studies have suggested that in the era of Drug-Eluting Stents(DES) are one of the causes of In-Stent Restenosis(ISR) of Stent Fracture(SF). The present study sought to evaluate clinical characteristics of patients with stent fracture after successful DES implantation. The 4,701 patients were selected for analysis who underwent a follow-up coronary angiography irrespective of ischemic symptoms. The overall incidence of SF was 32 patients(male:female=19:13, Av. age $62.44{\pm}9.8$year, 0.68%). Fractures of Sirolimus-Eluting Stents(SES), Paclitaxel-Eluting Stents(PES), Biolimus A9-Eluting Stents(BES), Everolimus-Eluting Etents(EES), Endothelial Progenitor Cell Capture Stent(EPC) and Zotarolimus-Eluting Stents(ZES) are accounted for 19(59.4%), 9(28.1%), 2(6.3%), 1(3.1%), 1(3.1%) and 0(0%) respectively. SF developed in the left Anterior Dscending(LAD) artery in 16 patients(50%) and in complex(type B2, C) lesions in 25 patients(69.4%). Ten patients were treated with heterogenous DES, the rest being treated with either homogenous DES(3 patients), plain old balloon angioplasty(3 patients), or conservative medical treatment(17 patients). None of the patients with SF suffered from cardiac death during a follow-up period of $32.9{\pm}12.4$ months. The overall rate of DES fracture over up to 3.7 years of follow-up was 0.68% with higher incidence in SES than in PES. SF frequently occurred in the LAD artery and in complex lesions. Of the patients with SF, coronary intervention was performed only when the binary restenosis lesion was significant. During the follow-up, patients with SF have continued on combination antiplatelet therapy. There is a very low rate of major adverse cardiac events(post-detection of SF), especially cardiac death associated with SF.